Literature DB >> 26165586

Gleason Score Determination with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Prostate Biopsies--Are We Gaining in Accuracy?

Camille Lanz1, François Cornud2, Frédéric Beuvon3, Arnaud Lefèvre2, Paul Legmann2, Marc Zerbib1, Nicolas Barry Delongchamps4.   

Abstract

PURPOSE: We evaluated the accuracy of prostate magnetic resonance imaging- transrectal ultrasound targeted biopsy for Gleason score determination.
MATERIALS AND METHODS: We selected 125 consecutive patients treated with radical prostatectomy for a clinically localized prostate cancer diagnosed on magnetic resonance imaging-transrectal ultrasound targeted biopsy and/or systematic biopsy. On multiparametric magnetic resonance imaging each suspicious area was graded according to PI-RADS™ score. A correlation analysis between multiparametric magnetic resonance imaging and pathological findings was performed. Factors associated with determining the accuracy of Gleason score on targeted biopsy were statistically assessed.
RESULTS: Pathological analysis of radical prostatectomy specimens detected 230 tumor foci. Multiparametric magnetic resonance imaging detected 151 suspicious areas. Of these areas targeted biopsy showed 126 cancer foci in 115 patients, and detected the index lesion in all of them. The primary Gleason grade, secondary Gleason grade and Gleason score of the 126 individual tumors were determined accurately in 114 (90%), 75 (59%) and 85 (67%) cases, respectively. Maximal Gleason score was determined accurately in 80 (70%) patients. Gleason score determination accuracy on targeted biopsy was significantly higher for low Gleason and high PI-RADS score tumors.
CONCLUSIONS: Magnetic resonance imaging-transrectal ultrasound targeted biopsy allowed for an accurate estimation of Gleason score in more than two-thirds of patients. Gleason score misclassification was mostly due to a lack of accuracy in the determination of the secondary Gleason grade.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; magnetic resonance imaging; neoplasm grading; prostatic neoplasms

Mesh:

Year:  2015        PMID: 26165586     DOI: 10.1016/j.juro.2015.07.021

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.

Authors:  R Diamand; M Oderda; W Al Hajj Obeid; S Albisinni; R Van Velthoven; G Fasolis; G Simone; M Ferriero; J-B Roche; T Piechaud; A Pastore; A Carbone; G Fiard; J-L Descotes; G Marra; P Gontero; E Altobelli; R Papalia; P Kumar; D Eldred-Evans; A Giacobbe; G Muto; V Lacetera; V Beatrici; T Roumeguere; A Peltier
Journal:  World J Urol       Date:  2019-01-16       Impact factor: 4.226

2.  Diagnostic evaluation of magnetization transfer and diffusion kurtosis imaging for prostate cancer detection in a re-biopsy population.

Authors:  Tristan Barrett; Mary McLean; Andrew N Priest; Edward M Lawrence; Andrew J Patterson; Brendan C Koo; Ilse Patterson; Anne Y Warren; Andrew Doble; Vincent J Gnanapragasam; Christof Kastner; Ferdia A Gallagher
Journal:  Eur Radiol       Date:  2017-12-08       Impact factor: 5.315

3.  Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.

Authors:  Chang Liu; Shi-Liang Liu; Zhi-Xian Wang; Kai Yu; Chun-Xiang Feng; Zan Ke; Liang Wang; Xiao-Yong Zeng
Journal:  Asian J Androl       Date:  2018 Sep-Oct       Impact factor: 3.285

4.  Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.

Authors:  Junxiao Liu; Biao Dong; Wugong Qu; Jiange Wang; Yue Xu; Shuanbao Yu; Xuepei Zhang
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.